STOCK TITAN

Caredx - CDNA STOCK NEWS

Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.

CareDx Inc (CDNA) delivers innovative non-invasive diagnostics for transplant patient care through advanced genomics and bioinformatics. This news hub provides investors and healthcare professionals with essential updates on the company's developments in precision medicine.

Key resources include: Earnings reports detailing financial performance in transplant diagnostics, regulatory updates on FDA-cleared testing solutions, and strategic partnership announcements expanding into hematology oncology. Track clinical trial outcomes validating AlloSure® monitoring and discover operational milestones in digital health integration.

Our curated collection enables efficient tracking of CDNA's progress in reducing invasive biopsies through blood-based dd-cfDNA analysis. Stay informed about innovations in kidney, heart, and lung transplant surveillance technologies that are reshaping organ rejection management.

Bookmark this page for real-time updates on CareDx's evidence-based diagnostic solutions and their impact on transplant care standards. Verify analysis dates and consult official filings for complete context on all developments.

Rhea-AI Summary
CareDx, Inc. (CDNA) will report financial results for Q4 and full year 2023 on February 28, 2024. The company focuses on healthcare solutions for transplant patients and caregivers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
conferences earnings
-
Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) announces its participation in the 2024 Tandem Meetings to showcase its digital solutions and advancements in cellular therapy and transplant monitoring. The company will present data on AlloHeme and AlloCell at the event, highlighting their potential in treatment response monitoring and relapse detection post-transplant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
-
Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) has been found to have not infringed on Natera, Inc.'s patent 10,655,180 but was found to have infringed on patent 11,111,544. The District of Delaware jury awarded Natera damages of $83,679,521 in lost profits and $12,535,500 in past royalties for alleged infringement by AlloSure from September 2021 through August 2023. CareDx intends to seek judicial review of the verdict. The decision does not impact patient or physician access to CareDx's current offerings, including AlloSure or AlloMap.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.53%
Tags
none
Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) is sponsoring the Annual American Society of Transplant Surgeons (ASTS) Winter Symposium to highlight new real-world use cases using its testing and digital solutions for improved patient risk management. The company is focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. Leading transplant experts will demonstrate how CareDx's molecular testing services, digital solutions, and risk assessment tools can improve access and outcomes within transplantation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.42%
Tags
-
Rhea-AI Summary
CareDx, Inc. (CDNA) reported preliminary financial results for Q4 and full year 2023, with revenue expected to be in the range of $279-280 million, above guidance for fiscal year 2023. Testing Services patient results grew by 4%, while revenue for Patient and Digital Solutions and Products is expected to increase by 29% and 14% year-over-year, respectively. The company repurchased 2.8 million shares of common stock for $26 million and maintained a strong balance sheet with approximately $235 million in cash and cash equivalents and marketable securities, with no debt. However, revenue for the fourth quarter is expected to decrease by approximately 3% compared to the third quarter, driven by the impact of the Medicare Billing Article on Testing Services revenue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
-
Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) is expanding its reach by offering its Transplant Pharmacy services to National Foundation for Transplants (NFT) patient members to help them manage the complexity of post-transplant medication adherence. The collaboration aims to provide greater support in adhering to complex medication schedules for transplant patients, reducing out-of-pocket costs, and ensuring personalized care with regular touch points.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.81%
Tags
none
Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) reported Q3 2023 financial results, including a 7% revenue increase to $67.2 million, raised revenue guidance to $274-278 million for 2023, and maintained a strong balance sheet with $268.2 million in cash and cash equivalents, and marketable securities, with no debt. The company also received Medicare coverage for HeartCare™ and AlloSure® Lung.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.9%
Tags
-
Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) will report financial results for the third quarter 2023 on November 8th, 2023. A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET. Interested individuals can dial 1-800-267-6316 (domestic) or 1-203-518-9783 (international) with Conference ID: CareDx. A live webcast will be available on CareDx's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.05%
Tags
conferences earnings
-
News
Rhea-AI Summary
CareDx, Inc. announces that Dr. Reginald Seeto will step down as CEO and President and transition to the role of Senior Advisor to the Chairperson. The company will establish an Office of the CEO consisting of Board Chairperson Michael Goldberg, CFO Abhishek Jain, and President of Patient and Testing Services Alexander Johnson. The Board has initiated a search for a permanent CEO. CareDx raises its 2023 revenue guidance to $274-278 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.98%
Tags
none
Rhea-AI Summary
CareDx, Inc. announces a leading presence at the 49th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) to showcase its portfolio of HLA typing solutions and AlloSeq HCT for hematopoietic stem cell monitoring.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
none
Caredx

Nasdaq:CDNA

CDNA Rankings

CDNA Stock Data

976.60M
53.24M
3.37%
94.9%
9.34%
Diagnostics & Research
Services-medical Laboratories
Link
United States
BRISBANE